TR1801-ADC in Patients With Tumors That Express c-Met

Inclusion Criteria: * Compliance with all study procedures and visits to the clinical research site * Locally advanced or metastatic disease that is not amenable to definitive therapy * Histologically confirmed diagnosis of a solid tumor which expresses c-Met * Must have progressed or have been intolerant to all available therapies known to confer clinical benefit appropriate for the patient's tumor type * Measurable baseline disease as defined by RECIST Version 1.1 * ECOG Performance Status 0-1 * Body weight within 40 and 150 kg * Clinical laboratory values with the limits as defined by the protocol * Not pregnant or breast feeding * Males and women of child-bearing potential must agree to use an effective method of contraception Exclusion Criteria: * Any disease or condition that may be considered to pose an increased risk from study treatment or the ability of the patient to participate and comply with study procedures * Treatment with anti-cancer therapy (including cytotoxic chemotherapy, major surgery, radiation, biologic and investigational agents) within 21 days before first dose of study treatment * Brain metastases that has not stabilized for at least 28 days after therapy and who have discontinued steroids for \<2 weeks * Unresolved adverse events \>= Grade 2 from prior anticancer therapies * Acute myocardial infarction, cerebral ischemic infarct, or other arterial thrombosis within 6 months of screening for this study. * Uncontrolled hypertension, unstable angina, or NYHA Class III/IV heart failure * History of capillary leak syndrome * Corticosteroid intolerance * History of anasarca * Untreated or uncontrolled bacterial, viral or fungal infection * HIV infection or active infection with hepatitis B or C * Significant liver disease * History of alcoholism or current alcoholism * Signs of significant portal hypertension * Significant kidney disease within 2 years * Active or unstable gallstone disease * Prior treatment with a c-Met targeted agent * Prior hypersensitivity reaction to treatment with another monoclonal antibody * QTcF \>=470 ms * Patients may not start any new herbal or dietary supplement within 4 weeks before initiation of study treatment nor while receiving study treatment * Administration of a live, attenuated vaccine within 28 days before the first dose of study treatment